CMA1 and chronic kidney disease: To inform ongoing and future clinical development programmes, we used predicted loss-of-function (pLoF) mutations within CMA1 to assess the potential clinical utility and safety of chymase inhibition for the treatment/prevention of HF, CKD and other conditions, in a large prospective biobank study.